Atlas Trials

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

RecordFirmDate
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease (NCT01616680)Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium2012-09-01
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment (NCT00845104)Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium2009-01-01
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461)Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium2008-08-01
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma (NCT00438984)Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium2006-12-01
Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission (NCT00031655)Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium2001-09-01
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation (NCT00002787)Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium1996-03-01
Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis (NCT01047072)Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Track Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium automatically

Every clearance here is in the API, with alerts when new ones post.